Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Gore

Showing results (21-30 of 34) with videos related to

Pageof 4
Sort By:
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
The Oncologist|November 9, 2025
Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)Liza C Villaruz, Benjamin Schluger, Hong Wang, et al.
Studies in Health Technology and Informatics|September 1, 2016
Key Data Elements in Myeloid LeukemiaJulian Varghese, Christian Holz, Phillip Neuhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
The Oncologist|December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancerMargaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
Blood Advances|May 5, 2023
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national studyGregory A Abel, Donnie Hebert, Cecilia Lee, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Blood Advances|March 22, 2023
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditionsAmy E DeZern, Johannes B Goll, R Coleman Lindsley, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Leukemia & Lymphoma|February 27, 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyRory M Shallis, Maximilian Stahl, Wei Wei, et al.
Pageof 4

Showing results (21-30 of 34) with videos related to

Sort By:
Pageof 4
NEJM Evidence|February 6, 2024
Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell LeukemiaJae H Park, Sean Devlin, Benjamin H Durham, et al.
The Oncologist|November 9, 2025
Phase Ib study of berzosertib, carboplatin, gemcitabine, and pembrolizumab in patients with squamous nonsmall lung cancer (ETCTN 10313)Liza C Villaruz, Benjamin Schluger, Hong Wang, et al.
Studies in Health Technology and Informatics|September 1, 2016
Key Data Elements in Myeloid LeukemiaJulian Varghese, Christian Holz, Phillip Neuhaus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
The Oncologist|December 3, 2025
NCI 10211: a phase II, single-arm study of berzosertib in combination with irinotecan in patients with advanced TP53 mutant gastroesophageal cancerMargaret C Wheless, Shannon Stockton, Heloisa P Soares, et al.
Blood Advances|May 5, 2023
Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national studyGregory A Abel, Donnie Hebert, Cecilia Lee, et al.
Leukemia|January 5, 2020
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDSJoshua F Zeidner, Hanna A Knaus, Amer M Zeidan, et al.
Blood Advances|March 22, 2023
Utility of targeted gene sequencing to differentiate myeloid malignancies from other cytopenic conditionsAmy E DeZern, Johannes B Goll, R Coleman Lindsley, et al.
Leukemia|March 6, 2020
Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international studyMaximilian Stahl, Rory M Shallis, Wei Wei, et al.
Leukemia & Lymphoma|February 27, 2020
Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapyRory M Shallis, Maximilian Stahl, Wei Wei, et al.
Pageof 4